

Supplement Table 2. Characteristics of all studies included in meta-analysis

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	F/U duration
				Inclusion criteria	Exclusion criteria		
Waldinger et al (1994) [1]	American Journal of Psychiatry	Netherlands	17	18–75 years old	ED, inhibited orgasm, alcohol and substance abuse, mental disorder, physical illness, use of medication including psychoactive medication	Placebo Paroxetine 20 mg daily	6 weeks
Kara et al (1996) [2]	Journal of Urology	Turkey	14	15–50 years, married patients with PE	ED, inhibited orgasm, alcohol or substance abuse, mental retardation	Placebo Fluoxetine 20 mg/40 mg daily	4 weeks
Waldinger et al (1997) [3]	Journal of Urology	Netherlands	34	18–60 years, history of primary PE	ED, alcohol or substance abuse, mental disorder, physical illness, psychoactive medication use, history of sexual abuse	Paroxetine 20 mg daily Paroxetine 40 mg daily	8 weeks
Biri et al (1998) [4]	International Urology and Nephrology	Turkey	37	IELT ≤1 min	Neurological or psychiatric disorder, alcohol or drug abuse	Placebo Sertraline 50 mg daily	4 weeks
Kim and Seo (1998) [5]	Journal of Urology	South Korea	144	IELT <2 min	Major psychiatric disorder, ED, urethritis or chronic prostatitis, significant medical illness, history of alcoholism or substance abuse, use of any drug that affect sexual function	Placebo Fluoxetine 40 mg daily Sertraline 100 mg daily Clomipramine 50 mg daily	4 weeks
Waldinger et al (1998) [6]	Journal of Clinical Psychopharmacology	Netherlands	51	18–65 years with PE	ED, alcohol or substance abuse/mental disorder/physical illnesses/concomitant medications/a history of sexual abuse of the patient or his partner	Placebo Fluvoxamine 100 mg daily Fluoxetine 20 mg daily Paroxetine 20 mg daily Sertraline 50 mg daily	6 weeks
McMahon (1998) [7]	Journal of Urology	Australia	37	Ejaculation time <1 min	ED, reduced sexual desire, inhibited male orgasm, chronic psychiatric or physical illness, alcohol or substance abuse, use of medication, including psychotropic medication	Placebo Sertraline 50 mg daily	12 weeks
Choi et al (1999) [8]	International Journal of Impotence Research	South Korea	50	Ejaculatory latency <3 min, sexual satisfaction rate <50%	Secondary PE, PE combined with ED or UTI, psychological problem, anti-depressant	Placebo Topical SS-cream 0.05 g Topical SS-cream 0.10 g Topical SS-cream 0.15 g Topical SS-cream 0.20 g	6 months
Abdel-Hamid et al (2001) [9]	International Journal of Impotence Research	Egypt	51	IELT <2 min	History of psychiatric disorder, current physical illness, previous medical history to affect sexual function, substance abuse (alcohol or drug), secondary PE	Clomipramine 25 mg on demand Sertraline 50 mg on demand Paroxetine 20 mg on demand Sildenafil 50 mg on demand Squeeze technique	4 weeks

Supplement Table 2. Continued 1

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Waldinger et al (2001) [10]	Journal of Clinical Psychopharmacology	Netherlands	48	18–65 years with PE	ED, alcohol or substance abuse, mental or physical illnesses, a history of sexual abuse, the partner's pregnancy or the wish for a child in the near future, the possibility of dangerous situations arising at work in the case of side effects	Placebo Nefazodone 400 mg daily Paroxetine 20 mg daily Sertraline 50 mg daily	6 weeks
Salonia et al (2002) [11]	Journal of Urology	Italy	80	IELT ≤1 min	Organic cause of PE, ED, low libido, major depression, alcohol, drug or substance abuse, organic illness causing limitation of SSRI or sildenafil use	Paroxetine 20 mg on demand Paroxetine 20 mg+Sildenafil 50 mg on demand	6 weeks
Novaretti et al (2002) [12]	Brazilian Journal of Urology	Brazil	50	PE complaint for at least 6 months	ED, use of antidepressant	Placebo Fluoxetine 20 mg daily	20 weeks
Atmaca et al (2002) [13]	International Journal of Impotence Research	Turkey	26	PE	ED, inhibited male orgasm, a severe physical illness, alcohol and any substance abuse or dependence, endocrinological state, psychotropic medication within last 2 weeks	Placebo Citalopram 20–60 mg daily	8 weeks
Manasia et al (2003) [14]	Journal of Urology	Spain	80	19–53 years old	ED, alcohol or substance abuse, psychopathology or mental retardation	Fluoxetine 90 mg weekly Fluoxetine 20 mg daily	3 months
Busato and Gallindo (2004) [15]	BJU International	Brazil	29	18–50 years with PE	Organic cause of PE, ED, alcohol or substance abuse, diabetes, hypertension	Placebo Topical Lidocaine 25 mg + Prilocaine 25 mg cream	8 weeks
Kiliç et al (2005) [16]	International Journal of Andrology	Turkey	21	IELT <2 min	Psychiatric or neurological disorder, history of sexual abuse, alcohol or substance abuse, drug affecting sexual function, pregnancy, ED, urethritis, chronic prostatitis, significant medical illness, thyroid dysfunction	Placebo Venlafaxine XR 75 mg daily	2 weeks
McMahon et al (2005) [17]	Journal of Sexual Medicine	Europe, Australia	126	18–65 years, IIEF ≥22, IELT ≤2 min	Treating ED, history of vascular disease past 6 months, using nitrates or cytochrome P450 inhibitor	Placebo Sildenafil 5–100 mg on demand	8 weeks

Supplement Table 2. Continued 2

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Safarinejad and Hosseini (2006) [18]	International Journal of Impotence Research	Iran	51	IELT <2 min	PE with ED, organic cause of PE including anatomical abnormalities, genital infection and neurological disorder, low libido, chronic depression, psychiatric or physical illness, alcohol, drug or substance abuse, organic illness causing limitation in SSRI use, use of psychotropic and antidepressant medication, serious relationship problems	Placebo Citalopram 20 mg daily	12 weeks
Safarinejad (2006) [19]	Clinical Neuropharmacology	Iran	309	IELT <2 min	PE with ED, organic cause of PE including anatomical abnormalities, genital infection and neurological disorder, low libido, chronic depression, psychiatric or physical illness, alcohol, drug or substance abuse, organic illness causing limitation in SSRI use, use of psychotropic and antidepressant medication, serious relationship problems	Placebo Dapoxetine 60 mg daily Paroxetine 20 mg daily	12 weeks
Pryor et al (2006) [20]	Lancet	United States	2,614	More than 18 years, IELT ≤2 min	ED or other sexual dysfunction, use of SSRI or TCA, history of major psychiatric disorder, use of other therapy for PE	Placebo Dapoxetine 30 mg on demand Dapoxetine 50 mg on demand	12 weeks
Arafa and Shamloul (2006) [21]	International Journal of Impotence Research	Egypt	147	IELT <2 min	ED, reduced sexual desire, inhibited male orgasm, chronic psychiatric or physical illness, alcohol or substance abuse, use of medication including psychotropic medication	Sertraline 50 mg daily to Placebo Placebo to Sertraline 50 mg daily	4 weeks
Wang et al (2007) [22]	International Journal of Urology	China	180	IELT <2 min	ED, low libido, major psychiatric or psychological illnesses including depression, alcohol, drugs or substances abuse, organic diseases causing limitation in using SSRI or sildenafil, use of other treatments for PE within the previous 3 months	Sildenafil 50 mg on demand Paroxetine 50 mg daily Squeeze technique	6 weeks
Hosseini and Yarmohammadi (2007) [23]	Urologia Internationalis	Iran	91	IELT <1 min	ED, alcohol and substance abuse, organic illness causing limitations in SSRI or sildenafil, low libido, major depression including other psychiatric or psychological illness, presence of psychopathology or mental retardation	Fluoxetine 20 mg on demand Fluoxetine 20 mg+Sildenafil 50 mg on demand	4 months
Dinsmore et al (2007) [24]	BJU International	United Kingdom	54	18–75 years with PE at least 6 months	ED, reduced sexual desire, inhibited male orgasm, chronic psychiatric or physical illness, alcohol or substance abuse, use of medication including psychotropic medication	Placebo Lidocaine 22.5 mg+Prilocaine 7.5 mg spray	4 weeks

Supplement Table 2. Continued 3

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Athanasios et al (2007) [25]	International Urology and Nephrology	Greece	20	PE	ED, severe physical illness, history of alcohol or any drug abuse	Placebo Duloxetine 20 mg BID	12 weeks
Arafa and Shamloul (2007) [26]	Therapeutics and Clinical Risk Management	Egypt	100	IELT <2 min	ED, reduced sexual desire, inhibited male orgasm, chronic psychiatric or physical illness, alcohol or substance abuse, use of medication including psychotropic medication	Fluoxetine 20 mg daily Escitalopram 10 mg daily Paroxetine 20 mg daily	4 weeks
Salem et al (2008) [27]	Journal of Sexual Medicine	United States	60	IIEF ≥ 22 , IELT <2 min	None	Placebo Tramadol 25 mg on demand	8 weeks
Safarnejad (2008) [28]	Journal of Clinical Psychopharmacology	Iran	192	PE	Patients with ED, reduced sexual desire, inhibited male orgasm, chronic psychiatric or physical illness, alcohol or substance abuse, use of medication including psychotropic medication	Placebo daily Venlafaxine 75 mg XR daily	12 weeks
Mattos et al (2008) [29]	Urologia Internationalis	Brazil	60	IELT <90 sec with IIEF >25	Diabetics, contraindications to the use of any medication involved in the study, abuse of alcohol or use of illicit narcotics	Placebo once a week Fluoxetine 90 mg once a week Placebo once a week +Tadalafil 20 mg on demand Fluoxetine 90 mg once a week +Tadalafil 20 mg on demand	12 weeks
Mathers et al (2009) [30]	Andrologia	Germany	72	Primary PE more than 1 year	Previous therapy of PE, who had known risk factors could possibly cause PE	Vardenafil 10 mg on demand Sertraline 50 mg on demand	6 weeks
Farnia et al (2009) [31]	Acta Medica Iranica	Iran	80	PE	ED, inhibited male orgasm, a severe physical or mental illness, the history of alcohol and any substance abuse or dependence, the presence of any endocrinological state, taking any psychotropic medication within last 2 weeks	Placebo on demand Citalopram 20 mg on demand	4 weeks

Supplement Table 2. Continued 4

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Dinsmore and Wyllie (2009) [32]	BJU International	Europe	290	PE patients ≥ 18 years	ED with IIEF-5 ≤ 21, a severe physical or psychological condition, tricyclic antidepressants, MAO inhibitors or SSRI any treatment for PE within 4 weeks, alcohol or drug abuse, drug sensitivity to amide-type local anaesthetics, pregnancy, a history of glucose-6-phosphate dehydrogenase deficiency or use of medications, use of class I or III anti-arrhythmic drugs	Placebo on demand 7.5 mg Lidocaine + 2.5 mg Prilocaine spray on demand	3 months
Buvat et al (2009) [33]	European Urology	North, South America, Europe, Middle East, Asia-Pacific	1,162	Men ≥ 18 years with IELT < 2 min at least 6 months	History of medical or psychiatric illness, uncontrolled hypertension or cardiac impairment, secondary PE, ED with IIEF < 21, partner sexual dysfunction, known hypersensitivity to SSRIs or serotonin norepinephrine reuptake inhibitors, concomitant use of SSRIs, tricyclic antidepressants, or other disallowed medications	Placebo on demand Dapoxetine 30 mg on demand Dapoxetine 60 mg on demand	24 weeks
Aversa et al (2009) [34]	International Journal of Impotence Research	Italy	40	Vardenafil naive with 18–35 years old, PEDT score ≥ 11, IIEF ≥ 22	IELT ≥ 1 min, IIEF < 22, other ED, treatment with SSRI, other treatment for PE, history of vascular disease, using organic nitrate or cytochrome P450 inhibitor, hyperthyroidism, hypogonadism, prostatitis	Placebo on demand Vardenafil 10 mg on demand	8 weeks
McMahon et al (2010) [35]	Journal of Sexual Medicine	Asia-Pacific regions	1067	≥ 18 years, IELT ≤ 2 min	Medical or psychiatric illness, history of medical events that onset of PE, ED with IIEF < 21, use of SSRI or tricyclic antidepressant, known hypersensitivity to SSRI or serotonin norepinephrine reuptake inhibitor	Placebo on demand Dapoxetine 30 mg on demand Dapoxetine 60 mg on demand	4 weeks
Alghobary et al (2010) [36]	Journal of Sexual Medicine	Egypt	35	PE at least 3 months with 20–50 years	Taking medications that may affect ejaculation at least 4 weeks. Major psychiatric illness	Tramadol 50 mg on demand Paroxetine 20 mg on demand	6 weeks
Carson and Wyllie (2010) [37]	Journal of Sexual Medicine	North America, Poland	249	PE ≥ 18 years	IIEF ≤ 21, physical or psychological illness, use of antidepressant or MAO inhibitor or SSRI, use of any treatment for PE, alcohol or drug abuse, sensitivity to amide-type local anaesthetics, use of class I or III anti-arrhythmic drug	Placebo on demand 7.5 mg Lidocaine + 2.5 mg Prilocaine spray on demand	3 months

Supplement Table 2. Continued 5

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Rezakhaniha and Sirosbakht (2010) [38]	Iranian Journal of Reproductive Medicine	Iran	77	PE patients including who had anxiety disorder	Erection impotency, urogenital infection, systemic or neurological disorders, psychological problems, alcoholism, drug abuse	Fluoxetine 20 mg daily Citalopram 40 mg daily	4 weeks
Zhang et al (2012) [39]	International Journal of Andrology	China	78	IELT <2 min, IIEF-5 >21, 18-35 years, previously treated with antidepressant drugs but not/ poorly responded or dislike oral medications	Balanitis, bleeding disorder, keloid formation, psychological medication	Circumcision Selective resection of dorsal nerve	6 months
Pastore et al (2012) [40]	International Journal of Andrology	Italy	34	IELT <1 min	ED, phimosis, history of prostatitis, frenulum brevis	Pelvic floor muscle rehabilitation Dapoxetine 30 mg on demand Dapoxetine 60 mg on demand	12 weeks
Kaynar et al (2012) [41]	Urology	Turkey	60	IELT ≤1 min	ED (IIEF <23), anatomic or organic disorders of the urogenital system, urogenital infection, sex hormone disorders, medications that can affect ejaculation, a low libido, chronic depression, psychiatric or physical disorders, alcohol, drug, or substance abuse, use of psychotropic or antidepressant medication, take medication for PE, hypersensitive to tramadol	Placebo on demand Tramadol 25 mg on demand	8 weeks
Bar-Or et al (2012) [42]	European Urology	United States	604	IELT <1 min, 18-65 years	History of other psychiatric disorders requiring therapy, medication, suicide risk, physical illnesses, Other sexual dysfunction including ED as defined by the DSMIV-TR criteria, sexual intercourse usually less than once per week, partner sexual dysfunction, current use of dapoxetine or tramadol, sensitivity to phenylethone, history of abuse of prescription or illegal addictive drugs, use of medication within 30 d of screening with potential to cause sexual dysfunction	Placebo on demand Tramadol 62 mg ODT on demand Tramadol 89 mg ODT on demand	18 weeks
Abdallah et al (2012) [43]	Andrologia	Egypt	49	IELT ≤2 min, circumcised	Sexual disorder, chronic psychiatric disease, hypertension, diabetes, alcohol or substance abuse, previous treatment of PE	Hyaluronic acid gel 2 mL injection	3 months

Supplement Table 2. Continued 6

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Khan and Rasaily (2013) [44]	Indian Journal of Psychological Medicine	India	60	20-45 years	ED, chronic psychiatric or systemic disease, alcohol or substance abuse	Placebo daily Placebo on demand Tramadol 100 mg daily Tramadol 100 mg on demand	8 weeks
McMahon et al (2013) [45]	Journal of Sexual Medicine	North, South America, Europe, Middle East, Asia-Pacific	222	IELT ≤2 min, over 18 years, IIEF ≥21	Serious physical or mental health, previous event or condition associated with PE, allergy to SSRI, drug abuse history, DSM-IV-TR psychiatric disorder	Placebo on demand Dapoxetine 30 mg on demand	12 weeks
Lee et al (2013) [46]	Journal of Sexual Medicine	South Korea	118	PE with 30-70 years, PEDT score ≥11	IIEF <22, self-reported sexual dysfunction, abuse of alcohol or substance, history of medical or psychiatric illness, use of SSRI, TCA, PDES inhibitor, contraindication of study medication	Dapoxetine 30 mg+Placebo on demand Dapoxetine 30 mg +Mirode-nafil 50 mg on demand	12 weeks
Shinghal et al (2013) [47]	Journal of Sexual Medicine	Netherlands, United States	77	18-55 years, IELT <65 sec	IIEF <22, medical or psychiatric illness, low libido, alcohol, drug or substance abuse, SSRI use, use of psychotropic and antidepressant medication	Placebo on demand Epelsiban 50 mg on demand Epelsiban 100 mg on demand	8 weeks
Gameel et al (2013) [48]	Arab Journal of Urology	Egypt	144	IELT <2 min	IIEF <22, drug abuse, Diabetes, urogenital disease, hepatic or renal impairment, psychiatric medication	Placebo on demand Tramadol 50 mg on demand Sildenafil 50 mg on demand Paroxetine 20 mg on demand Lidocaine 2.5% gel	4 weeks
Eassa and El-Shazly (2013) [49]	Asian Journal of Andrology	Egypt	300	25-50 years with PE	Secondary PE, sexual dysfunction, current physical illness, history of psychiatric or neurological disorder, substance abuse, taking drug known to affect sexual function	Tramadol 25 mg on demand Tramadol 50 mg on demand Tramadol 100 mg on demand	24 weeks
Akin et al (2013) [50]	Iranian Red Crescent Medical Journal	Turkey	108	PE	Drug abuse, sexual disorder, chronic prostatitis, using SSRI for PE	Sildenafil 4 mg daily Tamsulosin 0.4 mg daily Alfuzosin 10 mg daily Terazosin 5 mg daily Doksazosin 4 mg daily	2 weeks
Simsek et al (2014) [51]	Asian Journal of Andrology	Turkey	150	PE with 30-36 years	ED, low libido, major psychiatric or psychological illness, alcohol, drugs or substances abuse, organic diseases causing limitation in using SSRIs	Dapoxetine 30 mg on demand Dapoxetine 60 mg on demand Paroxetine 20 mg daily	4 weeks

Supplement Table 2. Continued 7

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Shi et al (2014) [52]	International Journal of Urology	China	41	>18 years, IELT <2 min, CIPE-5 <18	Acquired PE, psychiatric history, previous surgery or medication that affects sexual function, ED, severe hypertension, diabetes, coronary disease, poor general health	Soak in placebo Soak in RTX solution	4 weeks
Rezakhanlha and Siroosbakhsh (2014) [53]	Biosciences Biotechnology Research Asia	Iran	113	>18 years	Hypersensitivity to experimental drug	Citalopram 20 mg on demand Citalopram 20 mg daily	8 weeks
Kirecci et al (2014) [54]	Andrologia	Turkey	16	IELT <1 min	ED, low libido, history of sexual abuse, chronic prostatitis, infravesical obstruction, organic, neurological, psychiatric disorder, psychoactive medication user, Diabetes, cancer	Paroxetine 20 mg daily Sertraline 50 mg daily	4 weeks
Otunctemur et al (2014) [55]	Andrologia	Turkey	60	IELT <1 min	Diabetes, chronic disorder, ED, heavy smoker	Fluoxetine 20 mg daily Paroxetine 20 mg daily Sertraline 50 mg daily	4 weeks
Kirecci et al (2014) [56]	Andrologia	Turkey	60	PE	Diabetes, hypertension, vascular disorder, renal failure, endocrine disorder, previous genitourinary surgery, psychiatric disorder, intermittent PE, heavy smoker	Fluoxetine 20 mg daily Paroxetine 20 mg daily Sertraline 50 mg daily	4 weeks
Saadat et al (2015) [57]	Current Pharmaceutical Biotechnology	Iran	40	PE	Hypersensitivity to caffeine, cardiac problems, liver, kidney, thyroid dysfunction, psychological problem, overweight, heavy smoker	Placebo on demand Caffeine 100 mg on demand	3 weeks
Polat et al (2015) [58]	Andrologia	Turkey	150	Primary PE, 20-41 years	ED, Diabetes, low libido, major psychiatric or psychological illness, alcohol, drugs or substance abuse, contraindication of SSRI or PDE-5 inhibitor	Paroxetine 20 mg daily Tadalafil 20 mg on demand Paroxetine 20 mg daily + Tadalafil 20 mg on demand	4 weeks
Ozcan et al (2015) [59]	International Urology and Nephrology	Turkey	80	PE	Organic cause of PE, ED, low libido, psychiatric or psychological illness, alcohol, drugs or substance abuse, organic illness causing limitation in SSRI	Duloxetine 40 mg daily Paroxetine 20 mg daily	4 weeks
Kurkar et al (2015) [60]	Urology Annals	Egypt	125	PE with 20-55 years	ED, Diabetes, hepatic or renal insufficiency, neurological or psychiatric disorder, drug abuse	Placebo on demand Tramadol 50 mg on demand Tramadol 100 mg on demand	2 months
Ketabchi (2015) [61]	Nephro-Urology Monthly	Iran	126	PE with 24-57 years	History of psychiatric problem	Placebo daily Clomiphene 50 mg daily	12 weeks
Sahin et al (2016) [62]	Urologia Internationalis	Turkey	111	IELT <1 min	Organic cause of PE, ED with IIEF <21, sexual dysfunction, low libido, prostatitis, psychiatric or psychological illness, alcohol, drug or substance abuse, organic disorder that contraindication of SSRI	Dapoxetine 30 mg on demand Dapoxetine 60 mg on demand Acupuncture Sham acupuncture	4 weeks

Supplement Table 2. Continued 8

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Pavone et al (2017) [63]	Archivio Italiano di Urologia, Andrologia	Italy	276	IELT \leq 2 min, PEDT >9	Psychiatric disorder, drug and alcohol abuse, severe chronic disease, neoplastic disease	Dapoxetine (30–60 mg) on demand Group psychotherapy Dapoxetine +group psychotherapy	4 months
Dell'Atti et al (2017) [64]	European Review for Medical and Pharmacological Sciences	Italy	78	IIEF \leq 21	Use of TCA or SSRI, any treatment of PE, anti-arrhythmic drug, history of alcohol or drug abuse, pregnancy	Lidocaine spray on demand Tadarafil 5 mg daily Lidocaine spray on demand+ Tadarafil 5 mg daily	3 months
Homayuonfar et al (2018) [65]	Advanced Biomedical Research	Iran	72	IELT \leq 2 min., 20–50 years, PEDT score >8	History of psychiatric disorder, diabetes, renal insufficiency, liver disease, dyslipidemia, Hypertension, hypothyroidism or hyperthyroidism, cardiac arrhythmia, other sexual dysfunction, medication affecting ejaculatory function	Placebo daily Tamarind seed powder daily Paroxetine 20 mg daily	4 weeks
Kilinc et al (2018) [66]	Andrologia	Turkey	105	18–45 years	Use of medicine for endocrinological, metabolic, chronic systemic, psychiatric disease, use of alcohol or addictive substance, Peyronie's disease, chronic prostatitis, urethritis, active UTI, previous treatment of PE, absence of regular physical activity	Dapoxetine 30 mg on demand Moderate physical activity minimal physical activity	30 days
Hamidi-Madani et al (2018) [67]	Journal of Reproduction and Infertility	Iran	133	18–55 years, IELT \leq 1 min	Secondary PE, sexual dysfunction according to IIEF, history of major psychiatric disorder, endocrine disease, prostatitis, urogenital infection, drug or alcohol abuse, use or sensitivity of paroxetine or tramadol	Placebo on demand Tramadol 50 mg on demand Paroxetine 20 mg on demand	12 weeks
Abu El-Hamad and Abdelhamed (2018) [68]	Andrologia	Egypt	250	IELT \leq 1 min, age \geq 20	Diabetes, renal or hepatic disease, chronic prostatitis, neurological disease, central nervous system medication	Placebo on demand Paroxetine 30 mg on demand Dapoxetine 30 mg on demand Sildenafil 50 mg on demand Dapoxetine 30 mg +Sildenafil 50 mg on demand	6 weeks
Choi et al (2019) [69]	Journal of Urology	South Korea	159	20–65 years, PEDT >9, IELT <2 min	ED with IIEF \leq 21, serious cardiovascular or cerebrovascular disease within 6 months, uncontrolled hypertension or Diabetes, major psychiatric or neurological disorder, TCA, MAO inhibitor or SSRI medication, hypersensitivity to TCA, history of organic illness	Placebo on demand Clomipramine 1.5 mg on demand	12 weeks

Supplement Table 2. Continued 9

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
Siroobakht et al (2019) [70]	International Brazilian Journal of Urology	Iran	480	20–75 years	Neurologic or psychological disorder, genital infection, history of pelvic surgery, Diabetes, alcohol or drug abuse, ED, use of PDE5 inhibitor	Sertraline 50 mg BID Fluoxetine 20 mg BID Paroxetine 20 mg BID Citalopram 20 mg BID	8 weeks
McMahon et al (2019) [71]	Journal of Sexual Medicine	United States, Australia	83	18–60 years, IELT ≤1 min	ED with IIEF <22, intracavernosal injection, penile implant, SSRI, TCA, MAO inhibitor, alpha blocker, 5α-reductase inhibitor, topical anesthetics, tramadol use	Placebo on demand Cilostiban (400–800 mg) on demand	4 weeks
Liu et al (2019) [72]	Journal of Sexual Medicine	China	92	18–45 years, IIEF-5 >21, IELT <1 min No circumcised	Balanitis, bleeding disorder, keloid formation, psychiatric medication	Selective dorsal neurectomy+circumcision Circumcision	6 months
Althof et al (2019) [73]	Journal of Sexual Medicine	United States	231	18–60 years, IELT ≤1 min	IELT >2 min, IIEF <22, PDE5 inhibitor, SSRI, MAO inhibitor, α-blocker, 5α-reductase inhibitor, tramadol use	Placebo on demand Cligosiban 400 mg on demand Cligosiban 800 mg on demand Cligosiban 1200 mg on demand	8 weeks
Alahwany et al (2019) [74]	International Journal of Impotence Research	Egypt	30	IELT ≥1 min	ED, abnormal TSH, testosterone, prolactin level, prostatitis, history of drug abuse, psychiatric disorder, no circumcision	Saline 2 mL injection Hyaluronic acid 2 mL injection	1 month
Rehman et al (2020) [75]	Cureus	Pakistan	106	35–40 years, IELT ≤1 min	Low libido, ED, psychiatric or psychological disorder, organic illness which limit the use of SSRI, history of treatment of PE within 3 months	Tramadol 50 mg on demand Paroxetine 20 mg on demand	8 weeks
Panda et al (2020) [76]	Journal of Medicinal Food	India	116	IELT ≤1 min, 18–50 years	ED or other sexual dysfunction, psychiatric or psychological illness, chronic mental disorder or medication that limit dosage of pregabalin, secondary PE	Placebo on demand Pregabalin 75 mg on demand Pregabalin 150 mg on demand	2 weeks
Sahan et al (2020) [77]	Andrologia	Turkey	114	IELT ≤1 min, AIPE score <30	Lower urinary tract symptom or chronic pelvic pain which the reasons for secondary PE, ED, IIEF <21, low testosterone level, pregnancy, previous medication for PE, history of thyroid dysfunction, neurological disorder, psychiatric disorder, mental disorder, substance abuse, previous antidepressant medication	Sertraline 50 mg on demand Sertraline 100 mg on demand Dapoxetine 30 mg on demand Sertraline 50 mg daily	8 weeks
Alghobary et al (2020) [78]	Andrologia	Egypt	55	SHIM score ≥22, IELT ≤1 min	ED, chronic medical or psychological disorder, drug intake that influence ejaculation, libido or erection past 8 weeks.	Dapoxetine 60 mg on demand Lidocaine 10% spray	12 weeks

Supplement Table 2. Continued 9

Author (year)	Journal	Country	No. of patients	Subject description		Experimental description	
				Inclusion criteria	Exclusion criteria	Treatment	F/U duration
El Najjar et al (2020) [79]	Journal of Sexual Medicine	Egypt	116	IELT ≤1 min, 18–50 years	Lower urinary tract symptom or chronic pelvic pain which the reasons for secondary PE, ED, IIEF <21, low testosterone level, pregnancy, previous medication for PE, history of thyroid dysfunction, neurological disorder, psychiatric disorder, mental disorder, substance abuse, previous antidepressant medication	Placebo on demand Pregabalin 75 mg on demand Pregabalin 150 mg on demand	2 weeks
Siroosbakht et al (2021) [80]	Asian Journal of Urology	Iran	240	20–65 years with PE	Neurologic disorder, psychological disorder, urinary or genital infection, history of pelvic surgery, Diabetes, alcohol and drug abuse	Sertraline 50 mg BID Sertraline 50 mg on demand	8 weeks
Rodríguez et al (2021) [81]	PLoS One	Spain	40	Over 18 years, PEDT score ≥ 11, IELT ≤2 min	History of alcohol abuse or dependence, psychological treatment before 6 months, Diabetes, habitual use of recreational drugs (except tobacco and caffeine)	Sphincter exercise Sphincter exercise+masturbation device	8 weeks
Mohseni Rad et al (2021) [82]	Urology Journal	Iran	120	20–50 years, IELT ≤2 min	Diabetes, heart disease, high blood pressure, thyroid disease, sexually transmitted disease, psychiatric illness treated with psychiatric medication, ED	Dapoxetine 30 mg on demand Paroxetine 20 mg daily Paroxetine 20 mg daily+Tadalafil 50 mg on demand Dapoxetine 30 mg on demand +Tadalafil 50 mg on demand	4 weeks
Abu El-Hamd (2021) [83]	International Journal of Impotence Research	Egypt	150	≥20 years, circumcised	IIEF ≥22, chronic prostatitis, Diabetes, renal or liver disease, thyroid disease, neurological or psychiatric disease, allergic reaction to local anesthetics or alcohol, central nervous system medication or treatment for PE in previous 3 months	Placebo Lidocaine 5% spray	8 weeks
Mohamed Gharib et al (2022) [84]	Arab Journal of Urology	Egypt	160	18–65 years with PE	Neurogenic disorder, parkinsonism, diabetes, active UTI, chronic prostatitis, chronic renal failure, Peyronie's disease, endocrine disorder, thyroid dysfunction, taking medication for PE, drug affecting erectile function	Placebo daily Tadalafil 50 mg daily	3 months
Haghighi et al (2022) [85]	Journal of Psychiatric Research	Iran	46	18–65 years with PE	Treatment for PE previous, neurological disorder, psychiatric disorder, psychoactive drug	Placebo on demand Modafinil 100 mg on demand	4 weeks
Abou Faddan et al (2022) [86]	Arab Journal of Urology	Egypt	55	IELT ≤1 min, 20–35 years	IIEF ≥22, Diabetes, hypertension, taking medication	Placebo daily Tadalafil 5 mg daily	3 months

ED, Erectile dysfunction; PE, Premature ejaculation, IELT, Intra vaginal Ejaculation Latency Time, UTI, Urinary tract infection; XR, Extended-release; IIEF, International Index of Erectile function; SSRI, Selective serotonin reuptake inhibitor; BID: 2 in day, TCA, Tricyclic antidepressant; PEDT, Premature Ejaculation Diagnostic Tool; MAO, Monoamine oxidase inhibitor; ODT, Orally disintegrating tablet; DSM-IV-TR: diagnostic and statistical manual of mental disorders, fourth edition, text revision, PDE5 inhibitor, Phosphodiesterase 5 inhibitor; RTx: resinfertoxin, TSH: thyroid-stimulating hormone, CIPE-5, Chinese index of Premature ejaculation; AIPE, Arabic Index of Premature ejaculation; SHIM, Sexual Health Inventory for Men.

REFERENCES

1. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. *Am J Psychiatry* 1994;151:1377-9.
2. Kara H, Aydin S, Yücel M, Agargün MY, Odabaş O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. *J Urol* 1996;156:1631-2.
3. Waldinger MD, Hengeveld MW, Zwinderman AH. Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. *Br J Urol* 1997;79:592-5.
4. Biri H, Isen K, Sinik Z, Onaran M, Küpeli B, Bozkirli I. Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. *Int Urol Nephrol* 1998;30:611-5.
5. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. *J Urol* 1998;159:425-7.
6. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. *J Clin Psychopharmacol* 1998;18:274-81.
7. McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. *J Urol* 1998;159:1935-8.
8. Choi HK, Xin ZC, Choi YD, Lee WH, Mah SY, Kim DK. Safety and efficacy study with various doses of SS-cream in patients with premature ejaculation in a double-blind, randomized, placebo controlled clinical study. *Int J Impot Res* 1999;11:261-4.
9. Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. *Int J Impot Res* 2001;13:41-5.
10. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. *J Clin Psychopharmacol* 2001;21:293-7.
11. Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. *J Urol* 2002;168:2486-9.
12. Novaretti JPT, Pompeo ACL, Arap S. Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. *Braz J Urol* 2002;28:116-22.
13. Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. *Int J Impot Res* 2002;14:502-5.
14. Manasia P, Pomerol J, Ribè N, Gutierrez del Pozo R, Alcover Garcia J. Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation. *J Urol* 2003;170:164-5.
15. Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. *BJU Int* 2004;93:1018-21.
16. Kiliç S, Ergin H, Baydıncı YC. Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. *Int J Androl* 2005;28:47-52.
17. McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker N, Haughie S, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. *J Sex Med* 2005;2:368-75.
18. Safarinejad MR, Hosseini SY. Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. *Int J Impot Res* 2006;18:164-9.
19. Safarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. *Clin Neuropharmacol* 2006;29:243-52.
20. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. *Lancet* 2006;368:929-37.
21. Arafa M, Shamloul R. Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire. *Int J Impot Res* 2006;18:534-8.
22. Wang WF, Wang Y, Minhas S, Ralph DJ. Can sildenafil treat primary premature ejaculation? A prospective clinical study. *Int J Urol* 2007;14:331-5.
23. Hosseini MM, Yarmohammadi H. Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation.

Urol Int 2007;79:28-32.

24. Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. *BJU Int* 2007;99:369-75.
25. Athanasios Z, Polyanthi P, George K. The efficacy of duloxetine in the treatment of premature ejaculation. *Int Urol Nephrol* 2007;39:115-8.
26. Arafa M, Shamloul R. A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. *Ther Clin Risk Manag* 2007;3:527-31.
27. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. *J Sex Med* 2008;5:188-93.
28. Safarinejad MR. Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. *Andrologia* 2008;40:49-55.
29. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. *Urol Int* 2008;80:162-5.
30. Mathers MJ, Klotz T, Roth S, Lümmer G, Sommer F. Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. *Andrologia* 2009;41:169-75.
31. Farnia V, Raisi F, Mohseni MG, Atharikia D, Ghafari Z. On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. *Acta Med Iran* 2009;47:353-7.
32. Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. *BJU Int* 2009;103:940-9.
33. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. *Eur Urol* 2009;55:957-67.
34. Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G, et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. *Int J Impot Res* 2009;21:221-7.
35. McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. *J Sex Med* 2010;7(1 Pt 1):256-68.
36. Alghobary M, El-Bayoumy Y, Mostafa Y, Mahmoud el-HM, Amr M. Evaluation of tramadol on demand vs. daily paroxetine as a long-term treatment of lifelong premature ejaculation. *J Sex Med* 2010;7:2860-7.
37. Carson C, Wyllie M. Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. *J Sex Med* 2010;7:3179-89.
38. Rezakhaniha B, Sirosbakht S. Efficacy of selective serotonin reuptake inhibitor (SSRI) in patient with premature ejaculation. *Iran J Reprod Med* 2010;8:55-9.
39. Zhang GX, Yu LP, Bai WJ, Wang XF. Selective resection of dorsal nerves of penis for premature ejaculation. *Int J Androl* 2012;35:873-9.
40. Pastore AL, Palleschi G, Leto A, Pacini L, Iori F, Leonardo C, et al. A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. *Int J Androl* 2012;35:528-33.
41. Kaynar M, Kilic O, Yurdakul T. On-demand tramadol hydrochloride use in premature ejaculation treatment. *Urology* 2012;79:145-9.
42. Bar-Or D, Salottolo KM, Orlando A, Winkler JV. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. *Eur Urol* 2012;61:736-43.
43. Abdallah H, Abdelnasser T, Hosny H, Selim O, Al-Ahwany A, Shamloul R. Treatment of premature ejaculation by glans penis augmentation using hyaluronic acid gel: a pilot study. *Andrologia* 2012;44 Suppl 1:650-3.
44. Khan AH, Rasaily D. Tramadol use in premature ejaculation: daily versus sporadic treatment. *Indian J Psychol Med* 2013;35:256-9.
45. McMahon CG, Giuliano F, Dean J, Hellstrom WJ, Bull S, Tesfaye F, et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. *J Sex Med* 2013;10:2312-25.
46. Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, Yoo C, et al. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. *J Sex Med* 2013;10:2832-41.

47. Shinghal R, Barnes A, Mahar KM, Stier B, Giancaterino L, Condrey LD, et al. Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study. *J Sex Med* 2013;10:2506-17.
48. Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy Ael-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. *Arab J Urol* 2013;11:392-7.
49. Eassa BI, El-Shazly MA. Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation. *Asian J Androl* 2013;15:138-42.
50. Akin Y, Gulmez H, Ates M, Bozkurt A, Nuhoglu B. Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial. *Iran Red Crescent Med J* 2013;15:e13805.
51. Simsek A, Kirecci SL, Kucuktopcu O, Ozgor F, Akbulut MF, Sarilar O, et al. Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation. *Asian J Androl* 2014;16:725-7.
52. Shi B, Li X, Chen J, Su B, Li X, Yang S, et al. Resiniferatoxin for treatment of lifelong premature ejaculation: a preliminary study. *Int J Urol* 2014;21:923-6.
53. Rezakhanlani B, Siroosbakhsh S. Comparative study of therapeutic effects of two medicinal procedures of citalopram in premature ejaculation. *Biosci Biotechnol Res Asia* 2014;11:953-8.
54. Kirecci SL, Simsek A, Yuksel A, Gurdal H, Gurbuz ZG, Usanmaz S. Relevance of seminal plasma nitric oxide levels and the efficacy of SSRI treatment on lifelong premature ejaculation. *Andrologia* 2014;46:1169-75.
55. Otuntemur A, Ozbek E, Kirecci SL, Ozcan L, Dursun M, Cekmen M, et al. Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation: decreased nitric oxide is associated with premature ejaculation. *Andrologia* 2014;46:951-5.
56. Kirecci SL, Simsek A, Gurbuz ZG, Mimaroglu S, Yuksel A, Vural P, et al. Relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation. *Int J Urol* 2014;21:917-20.
57. Saadat SH, Ahmadi K, Panahi Y. The effect of on-demand caffeine consumption on treating patients with premature ejaculation: a double-blind randomized clinical trial. *Curr Pharm Biotechnol* 2015;16:281-7.
58. Polat EC, Ozbek E, Otuntemur A, Ozcan L, Simsek A. Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculation. *Andrologia* 2015;47:487-92.
59. Ozcan L, Polat EC, Otuntemur A, Ozbek E. Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation. *Int Urol Nephrol* 2015;47:283-7.
60. Kurkar A, Elderwy AA, Abulsorour S, Awad SM, Safwat AS, Altaher A. A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" tramadol for treatment of premature ejaculation. *Urol Ann* 2015;7:205-10.
61. Ketabchi AA. Clomiphene effects on idiopathic premature ejaculation. *Nephrourol Mon* 2015;7:e27281.
62. Sahin S, Bicer M, Yenice MG, Seker KG, Yavuzsan AH, Tugcu V. A prospective randomized controlled study to compare acupuncture and dapoxetine for the treatment of premature ejaculation. *Urol Int* 2016;97:104-11.
63. Pavone C, Abbadessa D, Gambino G, Scaduto G, Vella M. Premature ejaculation: pharmacotherapy vs group psychotherapy alone or in combination. *Arch Ital Urol Androl* 2017;89:114-9.
64. Dell'Atti L, Galosi AB, Ippolito C. A randomized single-center study to compare the efficacy and tolerability of tadalafil once daily plus lidocaine anesthetic spray on premature ejaculation. *Eur Rev Med Pharmacol Sci* 2017;21:1036-40.
65. Homayounfar A, Aminsharifi A, Salehi A, Sahraian A, Dehshari S, Bahrami M. A randomized double-blind placebo-controlled trial to assess the effect of tamarind seed in premature ejaculation. *Adv Biomed Res* 2018;7:59. Erratum in: *Adv Biomed Res* 2018;7:130.
66. Kilinc MF, Aydogmus Y, Yildiz Y, Doluoglu OG. Impact of physical activity on patient self-reported outcomes of lifelong premature ejaculation patients: results of a prospective, randomised, sham-controlled trial. *Andrologia* 2018;50:e12799.
67. Hamidi-Madani A, Motiee R, Mokhtari G, Nasseh H, Esmaeili S, Kazemnezhad E. The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. *J Reprod Infertil* 2018;19:10-5.
68. Abu El-Hamd M, Abdelhamed A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: a randomised placebo-controlled clinical trial. *Andrologia* 2018;50:e12829.
69. Choi JB, Kang SH, Lee DH, Kim YS, Jeon JS, Choi WS, et al. Efficacy and safety of on demand clomipramine for the treatment of pre-

- mature ejaculation: a multicenter, randomized, double-blind, phase III clinical trial. *J Urol* 2019;201:147-52.
70. Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. *Int Braz J Urol* 2019;45:1209-15.
 71. McMahon C, Althof S, Rosen R, Giuliano F, Miner M, Osterloh IH, et al. The oxytocin antagonist cligosiban prolongs intravaginal ejaculatory latency and improves patient-reported outcomes in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled proof-of-concept trial (PEPIX). *J Sex Med* 2019;16:1178-87.
 72. Liu Q, Li S, Zhang Y, Cheng Y, Fan J, Jiang L, et al. Anatomic basis and clinical effect of selective dorsal neurectomy for patients with lifelong premature ejaculation: a randomized controlled trial. *J Sex Med* 2019;16:522-30.
 73. Althof S, Osterloh IH, Muirhead GJ, George K, Girard N. The oxytocin antagonist cligosiban fails to prolong intravaginal ejaculatory latency in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled Phase IIb trial (PEDRIX). *J Sex Med* 2019;16:1188-98.
 74. Alahwany A, Ragab MW, Zaghoul A, Abdallah H, Mostafa T. Hyaluronic acid injection in glans penis for treatment of premature ejaculation: a randomized controlled cross-over study. *Int J Impot Res* 2019;31:348-55.
 75. Ur Rehman MF, Imran Zaidi A, Ul Haq T, Rafique S, Ali F. Comparison of the efficacy of tramadol and paroxetine in the management of premature ejaculation. *Cureus* 2020;12:e10725.
 76. Panda SK, Nirvanashetty S, Parachur VA, Mohanty N. A randomized double-blind placebo-control study to assess the efficacy and safety of OLNP-05 versus placebo for the treatment of subjects with premature ejaculation. *J Med Food* 2020;23:1006-13.
 77. Sahan A, Cubuk A, Ozkaptan O, Toprak T, Ozcan T, Ertas K, et al. Comparison of the safety and efficacy of the on-demand use of sertraline, dapoxetine, and daily use of sertraline in the treatment of patients with lifelong premature ejaculation: a prospective randomised study. *Andrologia* 2020;52:e13854.
 78. Alghobary M, Gaballah M, El-Kamel MF, State AF, Ismail SR, Selim MK, et al. Oral dapoxetine versus topical lidocaine as on-demand treatment for lifelong premature ejaculation: a randomised controlled trial. *Andrologia* 2020;52:e13558.
 79. El Najjar MR, El Hariri M, Ramadan A, Hefny Hashem AA. A double blind, placebo controlled, randomized trial to evaluate the efficacy and tolerability of on-demand oral pregablin (150 mg and 75 mg) in treatment of premature ejaculation. *J Sex Med* 2020;17:442-6.
 80. Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Comparative study of on-demand and daily use of sertraline in treatment of premature ejaculation: a randomized clinical trial. *Asian J Urol* 2021;8:209-14.
 81. Rodríguez JE, Picazo JA, Marzo JC, Piqueras JA, Reina L, Hidalgo G, et al. Efficacy of Sphincter Control Training and medical device in the treatment of premature ejaculation: a multicenter randomized controlled clinical trial. *PLoS One* 2021;16:e0257284.
 82. Mohseni Rad H, Zahirian Moghadam T, Hosseinkhani A, Nima Soluki N, Amani F. Comparison of Dapoxetine/Tadalafil and Paroxetine/Tadalafil combination therapies for the treatment of the premature ejaculation: a randomized clinical trial. *Urol J* 2021;19:138-43.
 83. Abu El-Hamd M. Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial. *Int J Impot Res* 2021;33:96-101. Erratum in: *Int J Impot Res* 2020;32:367.
 84. Mohamed Gharib T, Abdel-Al I, Elatreisy A, Kandeel W, El-Shaer W, Abdrabuh AM, et al. Short- and long-term follow-up results of daily 5-mg tadalafil as a treatment for erectile dysfunction and premature ejaculation. *Arab J Urol* 2022;20:49-53.
 85. Haghghi M, Jahangard L, Meybodi AM, Shayganfard M, Ahmadpanah M, Faryadres M, et al. Influence of modafinil on early ejaculation - results from a double-blind randomized clinical trial. *J Psychiatr Res* 2022;146:264-71.
 86. Abou Faddan AH, Gaber HD, Oamonov D. Effect of a tadalafil 5-mg single daily dose on lifelong premature ejaculation: a single-blinded placebo-controlled study. *Arab J Urol* 2022;20:100-4.